Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 2 Frequencies of metastatic sites, divided by molecular subtype (n = 744)

From: Metastatic behavior and overall survival according to breast cancer subtypes in stage IV inflammatory breast cancer

  HR+/HER2−
(n = 340)
HR+/HER2+
(n = 131)
HR−/HER2+
(n = 148)
HR−/HER2−
(n = 125)
p value
Type of metastasis per subtype
 Multiple sites 173 (50.9) 77 (58.8) 74 (50.0) 67 (53.6) 0.414
 Only one site 167 (49.1) 54 (41.2) 74 (50.0) 58 (46.4)
 Bone 102 (30.0) 30 (22.9) 24 (16.2) 21 (16.8) < 0.001
 Lung 17 (5.0) 2 (1.5) 8 (5.4) 12 (9.6)
 Liver 12 (3.5) 8 (6.1) 20 (13.5) 8 (6.4)
 Other# 36 (10.6) 14 (10.7) 22 (14.9) 17 (13.6)
All found metastases$
 Bones 243 (71.5) 90 (68.7) 75 (50.7) 52 (41.6) < 0.001
 Lung 102 (30.0) 41 (31.3) 35 (23.7) 51 (40.8) 0.023
 Liver 75 (22.1) 43 (32.8) 61 (41.2) 39 (31.2) < 0.001
 Brain 7 (2.1) 5 (3.8) 3 (2.0) 3 (2.4) 0.713
 Other/unknown 35 (10.3) 13 (9.9) 21 (14.2) 17 (13.6) 0.496
  1. p values indicated in italics are considered as statistically significant (p < 0.05). Abbreviations: HR hormone receptor, HER2 human epidermal growth factor receptor-2. #Including brain metastasis. $Cumulative percentage per subtype exceeds 100% due to the occurrence of multiple metastases at diagnosis